# Janssen Pharmaceuticals

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/janssen-pharmaceuticals/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer |
| OpenAlex ID | https://openalex.org/F4320337601 |
| ROR ID | https://ror.org/03qd7mz70 |
| Works | 7,140 |

## Funder papers

- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-reducing-serum-potassium-and-preventing-recurrent/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [Efficacy of acupuncture for migraine prophylaxis: A single-blinded, double-dummy, randomized controlled trial](https://scholariq.org/papers/efficacy-of-acupuncture-for-migraine-prophylaxis-a-single-blinded-double-dummy-2/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers](https://scholariq.org/papers/molecular-biomarkers-of-disease-outcomes-and-mechanisms-of-acquired-resistance/)
- [Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial](https://scholariq.org/papers/effects-of-canagliflozin-on-cardiovascular-renal-and-safety-outcomes-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.